PRACTICAL GUIDE | 2026
The parallel pathway most sponsors don't expect.
By Julio G. Martinez-Clark
CEO, bioaccess®
Last verified: September 2026 | General information only—not legal or regulatory advice. Rules change frequently; confirm the strategy with qualified regulatory counsel.
| Suggested URL slug | latam-ethics-committees-parallel-submissions |
|---|---|
| SEO title | Ethics Committees in Latin America: Parallel vs. Sequential Submissions | 2026 Guide |
| Meta description | In LATAM's fast markets, ethics committee and regulator submissions run in parallel — a designed-in accelerator. How pathway design, not IRB shopping, shapes the startup clock. |
| Suggested excerpt | Sponsors expect ethics review, then regulatory review. In Panama, Chile, El Salvador, and Costa Rica, both run at once — by design. How parallel submissions change the FIH startup clock. |
Sponsors expect a sequence: ethics committee first, regulator second. In Latin America's fast markets, that is not how it works. The ethics committee and the regulator receive submissions in parallel — a designed-in timeline accelerator that most sponsors never see coming. Here is how ethics committees in Latin America actually shape the startup clock, and why the sponsors who plan for parallelism start faster.
- bioaccess® — a first-in-human (FIH) contract research organization (CRO) running early-stage clinical trials across Latin America.
- FIH (first-in-human) — the first clinical use of a device or drug in people — typically a small, closely monitored early-feasibility study.
- Ethics committee — the independent body that reviews a trial's ethics — known as an IRB (institutional review board) in the United States.
- Regulator — the national health authority that authorizes the clinical trial — for example, INVIMA in Colombia or COFEPRIS in Mexico.
- Fast corridor — bioaccess®'s term for the fastest FIH startup markets in the region: Panama, Chile, El Salvador, and Costa Rica — typically 15–45 days to activation.
- Committee cadence — how often an ethics committee meets and issues decisions — a direct input to the startup clock.
Do the ethics committee and the regulator review in parallel or sequentially?
In the fast markets, in parallel. The ethics committee and the national regulator receive the submission at the same time and run their reviews concurrently. This is not a shortcut or a favor — it is the designed pathway. Sponsors who plan for a sequential process over-budget their startup clock by weeks they do not need to spend.
| Sequential submission | Parallel submission | |
|---|---|---|
| How it works | Ethics committee first; regulator after approval. | Both receive the submission at the same time. |
| Timeline math | The two review clocks add together. | The startup clock is the longer of the two — not the sum. |
| Where it applies | Markets without a parallel pathway. | The fast corridor: Panama, Chile, El Salvador, Costa Rica. |
| Planning risk | Over-budgeted startup; unnecessary delay. | Requires both packages submission-ready at once. |
Why does parallel submission change the timeline?
Sequential review adds the two clocks together. Parallel review runs them against each other — the startup clock becomes the longer of the two reviews, not the sum. In a fast market, that design choice is a meaningful part of how activation lands in weeks rather than months. It is also why the submission package has to be complete on day one: parallelism only works if neither reviewer is waiting on documents.
Which markets does this apply to?
The fast corridor: Panama, Chile, El Salvador, and Costa Rica. These are the markets where the parallel pathway is an established part of startup design. Outside the corridor, confirm the pathway market by market — do not assume parallelism travels. Pathway design starts with knowing which map you are on.
What does committee cadence have to do with the startup clock?
Committees meet on schedules, and those schedules are a line item in the startup clock — alongside translation, import permits, and contracting. Committee cadence, meeting frequency, and the national-versus-hospital pathway all shape how fast a parallel submission converts into an approval. We plan around the actual cadence of the actual committee reviewing the study — not a generic average, and not a number from a brochure.
How fast can activation actually be?
In Panama, we have seen activation in about 15 days. The ethics-submission ID number arrives in about three business days, and the regulator's follow-up requirements are typically minimal — in our experience, we barely get any requirements. Those are real outcomes from real programs, not a promised standard: the parallel pathway makes them possible, and execution makes them happen.
Designing the ethics pathway: a checklist
- Confirm whether the target market runs ethics and regulatory review in parallel or sequentially — before quoting the startup clock.
- Get both packages submission-ready at once; parallelism fails if either reviewer waits on documents.
- Confirm the actual committee's cadence during startup planning and build the clock from it.
- Resolve the national-versus-hospital pathway question where both exist.
- Use the universal submission package (protocol, IB, ICF, CRF, insurance, preclinical) to prevent rounds of committee questions — the most common preventable delay.
- Never select a committee for leniency; select the pathway for design.
Frequently asked questions
Should we submit to the ethics committee before the regulator?
In the fast-corridor markets, submit to both at once — that is the designed pathway. Planning for a sequential process over-budgets the startup clock.
Does parallel submission mean a less rigorous ethics review?
No. It is the same review, run concurrently. Parallelism changes timing, not standards.
Which is better: a hospital or a national ethics committee?
It depends on the market and the program. That is a pathway-design question, not a shopping question — confirm which pathways exist in the target market first.
How do we plan around committee meeting schedules?
Confirm the actual committee's cadence during startup planning and build the clock from it. This post states no per-country cadence as fact — cadence is verified program by program.
Is parallel submission available in Brazil or Mexico?
Confirm market by market. This post describes the fast corridor — Panama, Chile, El Salvador, and Costa Rica — where the parallel pathway is established.
What is the biggest preventable delay in ethics review?
An incomplete submission package cycling through rounds of committee questions. The universal six-document package is the prevention.
Design the pathway before you file
bioaccess® designs FIH startup pathways across Latin America — parallel submissions where the market supports them, committee cadence built into the clock, and a submission package that survives first review. Tell us your target markets; we will map the fastest honest route.
Talk with bioaccess® about your Latin America FIH strategyTalk with bioaccess® about your Latin America FIH strategy
References
- Parallel-submission practice described reflects bioaccess® programs in the fast-corridor markets (Panama, Chile, El Salvador, Costa Rica) and sponsor Q&A, 2021–2026 (all clients anonymized).
- Panama program outcomes cited (about 15-day activation; about three business days for the ethics-submission ID) are real program results, not guaranteed standards.
- No dedicated ethics-committee post previously existed on the bioaccess® blog.
- General: confirm the submission pathway and committee cadence for the specific market and committee before committing timelines.
Leave a Reply